Skip to content
Screener

Tango Therapeutics TNGX Q4 2025 Annual earnings

Reported March 5, 2026 · Before market open

Revenue-
EPS-$0.29Beat by $0.02
EPS estimate-$0.31

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$3.3M
EPS estimate-$0.34

Financials

Q4 2025

Income statement

See full
Revenue--100%
Operating income-$41.9M-2.3%
Net income-$38.7M-2.9%
EPS (diluted)-$0.30+11.8%

Balance sheet

See full
Cash & equivalents$112.3M+61.5%
Total debt$33.6M-8.0%
Total equity$346.2M+73.5%
Total assets$398.7M+26.0%

Cash flow

See full
Operating cash flow-$29.7M+18.9%
CapEx$222.0K+79.0%
Free cash flow-$29.9M+18.6%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.19B+259%
Enterprise value$1.11B+273%
P/S19.1×+11.2×

Profitability

See full
Operating margin-178.4%-58.2pp
Net margin-162.9%-52.4pp
FCF margin-224.3%-49.9pp

Returns & leverage

See full
Return on equity-37.2%-9.7pp
Debt / equity0.1×-0.1×
Current ratio16.3×+9.3×

FAQ

When did Tango Therapeutics report Q4 2025 earnings?
Tango Therapeutics (TNGX) reported Q4 2025 earnings on March 5, 2026 before market open.
What were Tango Therapeutics's Q4 2025 revenue and EPS?
Tango Therapeutics reported revenue of - and eps of $-0.29 for Q4 2025.
Did Tango Therapeutics beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.31 by $0.02.
How did Tango Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $4.1M a year earlier and eps grew 17.1% from $-0.35.
Where can I find Tango Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-092535) and the 10-K periodic report (0001193125-26-092518) directly on SEC EDGAR. The filing index links above go to sec.gov.